Skip to content

Neoveil® Versus TachoSil® for the Treatment of Pulmonary Air Leaks Following Lung Operation

Neoveil® Versus TachoSil® for the Treatment of Pulmonary Air Leaks Following Lung Operation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04065880
Enrollment
46
Registered
2019-08-22
Start date
2020-04-01
Completion date
2021-07-31
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolonged Air Leak, Postoperative Air Leak

Keywords

lung resection, TachoSil®, Neoveil®, air leak closure, drainage time

Brief summary

Postoperative prolonged air leak (PAL), referring to the passage of air from the lung parenchyma into the pleural space, is one of the most frequent postoperative complications after lung resection. To control air leak, there are two different products certified since years: TachoSil® and Neoveil®. This study is to investigate the difference of TachoSil® and Neoveil® in patients with PAL.

Interventions

topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.

OTHERNeoveil®

bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

Blinded participants and unblinded investigators and evaluators

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with a pulmonary air leak following open lung surgery, regardless of whether an anatomical or atypical resection was performed * Patients who are able to decide for themselves whether to participate in the study or not ( for example due to language problems, mental disorders, dementia of the participant) * Patients who are not family member or employee of the investigator

Exclusion criteria

* Inability to follow the procedures of the study, for example, due to language problems, mental disorders, dementia of the participant * Enrolment of the investigator, his/her family members, employees and other dependent persons

Design outcomes

Primary

MeasureTime frameDescription
time required till air leak closure has occurred (hours)end of the operation (0 hours) until removal of the chest tubes or re-operation in case of prolonged air leak (first postoperative day)time interval between end of the operation (closure of the skin) and air leak closure (less than 30ml on the digitalized drainage system).

Secondary

MeasureTime frameDescription
Incidence of air leak (binary outcome 0/1), i.e. air loss > 30mlend of the operation (0 hours) until removal of the chest tubes or re-operation in case of prolonged air leak (first postoperative day)Incidence of air leak (binary outcome 0/1), i.e. air loss \> 30ml
Intensity of air leak (continuous outcome, ml)end of the operation (0 hours) until removal of the chest tubes or re-operation in case of prolonged air leak (first postoperative day)Intensity of air leak (continuous outcome, ml)
Incidence of prolonged air leak (>10 days) (binary outcome 0/1)assessed at 10th postoperative dayIncidence of prolonged air leak (\>10 days) (binary outcome 0/1)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026